

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Suzhou Ribo Life Science Co., Ltd.**

**蘇州瑞博生物技術股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 6938)**

## **VOLUNTARY ANNOUNCEMENT**

### **PHASE II CLINICAL TRIAL APPLICATION SUBMISSION OF RBD1119 INJECTION FOR TREATMENT OF CORONARY ARTERY DISEASE**

This announcement is made by Suzhou Ribo Life Science Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide shareholders of the Company (the “**Shareholders**”) and potential investors with an update on the Group’s research and development progress.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce the successful submission of the phase II clinical trial application for the Company’s self-developed product RBD1119 Injection for treatment of coronary artery disease (CAD) at the European Medicines Agency.

CAD remains a leading cause of morbidity and mortality globally, driven by atherosclerotic plaque formation and associated thrombotic complications such as myocardial infarction and other ischemic events. Despite the widespread use of standard of care therapies, including antiplatelet and anticoagulant therapies, a substantial residual risk of thrombotic events remains in patients with stable CAD, even under optimized treatment. Current therapies are further limited by an increased risk of bleeding, restricting their intensity and long-term use in many patients.

RBD1119 Injection is a novel antithrombotic siRNA therapy that can provide effective and sustained protection against thrombosis while maintaining a favorable safety profile, particularly with respect to bleeding risk.

**RBD1119 Injection may not ultimately be successfully developed and commercialized. Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**Suzhou Ribo Life Science Co., Ltd.**  
**LIANG Zicai**  
*Chairman*

Hong Kong, May 28, 2026

*As of the date of this announcement, the executive Directors are Dr. LIANG Zicai, Dr. GAN Liming and Dr. ZHANG Hongyan, the non-executive Directors are Dr. QI Fei, Mr. LI Dongfang and Mr. LI Yuhui, and the independent non-executive Directors are Dr. YU Xuefeng, Mr. MA Chaosong and Mr. WANG Ruiping.*